ABSTRACT - 598913 The disclosure relates to the use of a combination comprising the MEK inhibitor N-{ 3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethyl；-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl} acetamide represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof, with a B-Raf inhibitor, particularly N-{ 3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl} -2,6-difluorobenzenesulfonamide represented by formula (II) or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of cancer.
